Informatie:
Fout:
ID
42777
Beschrijving
Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B; ODM derived from: https://clinicaltrials.gov/show/NCT00895596
Link
https://clinicaltrials.gov/show/NCT00895596
Trefwoorden
Versies (2)
- 03-08-16 03-08-16 -
- 17-09-21 17-09-21 -
Geüploaded op
17 september 2021
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Chronic Hepatitis B NCT00895596
Eligibility Chronic Hepatitis B NCT00895596
- StudyEvent: Eligibility
Similar models
Eligibility Chronic Hepatitis B NCT00895596
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
compensated chronic hepatitis b
Item
compensated chronic hepatitis b patient
boolean
C0524909 (UMLS CUI [1,1])
C0205432 (UMLS CUI [1,2])
C0205432 (UMLS CUI [1,2])
serum hbsag
Item
presence of serum hbsag for more than 6 months.
boolean
C0019168 (UMLS CUI [1])
hbeag with compensated liver disease
Item
presence of hbeag for more than 1 month with compensated liver disease
boolean
C0019167 (UMLS CUI [1])
C0023895 (UMLS CUI [2,1])
C0205432 (UMLS CUI [2,2])
C0023895 (UMLS CUI [2,1])
C0205432 (UMLS CUI [2,2])
ymdd mutants
Item
confirmation of ymdd mutants (m552v, m552i and its related double mutant at l528m) by genotyping of the ymdd motif using line probe assay (inno-lipa hbv dr assay)
boolean
C1717884 (UMLS CUI [1])
hbv dna
Item
screening hbv dna value higher than or equal to 1,000,000 copies/ml (measured by the cobas amplicor hbv monitor™ assay)
boolean
C3641250 (UMLS CUI [1])
alt
Item
screening alt value between 1.5 and 10 x uln
boolean
C0201836 (UMLS CUI [1])
co-infection with hepatitis c or d virus (hcv or hdv) or hiv
Item
co-infection with hepatitis c or d virus (hcv or hdv) or hiv
boolean
C0275524 (UMLS CUI [1])
C0220847 (UMLS CUI [2])
C0011220 (UMLS CUI [3])
C0019682 (UMLS CUI [4])
C0220847 (UMLS CUI [2])
C0011220 (UMLS CUI [3])
C0019682 (UMLS CUI [4])
pregnancy or breastfeeding
Item
pregnancy or breast-feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
treatment with nucleoside analogue or any other treatment for hbv
Item
previous treatment with nucleoside analogue or any other treatment for hbv except for lamivudine within 6 months prior to study entry
boolean
C1579410 (UMLS CUI [1])
C0019163 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C0019163 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
immunomodulatory agent or corticosteroids
Item
treatment with immunomodulatory agent or corticosteroids within 6 months prior to study entry.
boolean
C0005525 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
C0001617 (UMLS CUI [2])
decompensated liver disease
Item
de-compensated liver disease
boolean
C4075847 (UMLS CUI [1])
screening alpha-fetoprotein (afp), ultrasonography, indicative of hcc
Item
screening alpha-fetoprotein (afp) value > 20 ng/ml, and a follow-up ultrasonography performed prior to baseline shows findings indicative of hcc.
boolean
C0201539 (UMLS CUI [1])
C0041618 (UMLS CUI [2])
C2239176 (UMLS CUI [3])
C0041618 (UMLS CUI [2])
C2239176 (UMLS CUI [3])
anti-hbs
Item
presence of anti-hbs at screening
boolean
C0201478 (UMLS CUI [1])